MicroRNAs as the critical regulators of autophagy-mediated cisplatin response in tumor cells

Ghasaban, Faezeh Tolue; Maharati, Amirhosein; Akhlaghipour, Iman; Moghbeli, Meysam

doi:10.1186/s12935-023-02925-7

Cited by 12 publications

(5 citation statements)

References 209 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[18][19][20] Some micro-RNAs (miRNAs) are closely correlated with MDR induction because they regulate MDR relevant gene expression. [21][22][23] In the current study, we confirmed HCSP4 targeting specificity to CK2α and designed a novel liposomal DOX delivery formulation using HCSP4 as a targeting fragment and a newly identified miRNA (miR125a-5p) as the inhibitor of CK2α and MDR induction, then the new drug was tested for its HCC therapeutic efficacy and mechanism in vitro.…”

Section: Introductionmentioning

confidence: 61%

See 1 more Smart Citation

Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α

Zhao,

Cheng,

Bai

et al. 2024

Biotechnology Journal

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a digestive tract cancer with high mortality and poor prognosis, especially in China. Current chemotherapeutic drugs lead to poor prognosis, low efficacy, and high side effects due to weak targeting specificity and rapidly formed multidrug resistance (MDR). Based on the previous studies on the doxorubicin (DOX) formulation for cancer targeting therapy, we developed a novel DOX delivery formulation for the targeting chemotherapy of HCC and DOX resistant HCC. HCSP4 was previously screened and casein kinase 2α (CK2α) was predicted as its specific target on HCC cells in our lab. In the study, miR125a‐5p was firstly predicted as an MDR inhibiting miRNA, and then CK2α was validated as the target of HCSP4 and miR125a‐5p using CK2α‐/‐HepG2 cells. Based on the above, an HCC targeting and MDR inhibiting DOX delivery liposomal formulation, HCSP4/Lipo‐DOX/miR125a‐5p was synthesized and tested for its HCC therapeutic efficacy in vitro. The results showed that the liposomal DOX delivery formulation targeted to HCC cells specifically and sensitively, and presented the satisfied therapeutic efficacy for HCC, particularly for DOX resistant HCC. The potential therapeutic mechanism of the DOX delivery formulation was explored, and the formulation inhibited the expression of MDR‐relevant genes including ATP‐binding cassette subfamily B member 1 (ABCB1, also known as P‐glycoprotein), ATP‐binding cassette subfamily C member 5 (ABCC5), enhancer of zeste homolog 2 (EZH2), and ATPase Na+/K+ transporting subunit beta 1 (ATP1B1). Our study presents a novel targeting chemotherapeutic drug formulation for the therapy of HCC, especially for drug resistant HCC, although it is primarily and needs further study in vivo, but provided a new strategy for the development of novel anticancer drugs.

show abstract

Section: Introductionmentioning

confidence: 61%

“…[ 18–20 ] Some micro‐RNAs (miRNAs) are closely correlated with MDR induction because they regulate MDR relevant gene expression. [ 21–23 ]…”

Section: Introductionmentioning

confidence: 99%

Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α

Zhao,

Cheng,

Bai

et al. 2024

Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…Accumulating studies have demonstrated miRNAs directly target PI3K or its downstream components, which critically contributes to extensive cell events, including autophagy. , A previous study revealed that miR-155 mediated autophagy via directly targeting PI3K-AKT-mTOR in Schwann cells . We hypothesized that PI3K was also targeted by miR-155 to regulate Pec 1-induced autophagy inhibition in MH-S cells.…”

Section: Resultsmentioning

confidence: 92%

Pec 1 of Pseudomonas aeruginosa Inhibits Bacterial Clearance of Host by Blocking Autophagy in Macrophages

Jin,

Zhang,

Lin

et al. 2024

ACS Infect. Dis.

View full text Add to dashboard Cite

Pseudomonas aeruginosa (P. aeruginosa), a common opportunistic pathogen, is highly prone to chronic infection and is almost impossible to eradicate, especially attributed to virulence factors and adaptive mutations. In the present study, pseudomonas effector candidate 1 (Pec 1), a novel virulence factor of P. aeruginosa, was investigated, which inhibited bacterial clearance by the host and aggravated lung injury. Further, it demonstrated that Pec 1 inhibited miR-155 via suppressing integrin β3 expression, thereby activating PI3K-AKT-mTOR and inhibiting autophagy in macrophages. Additionally, the identification of Pec 1 in sputum was related to the bacterial load and assisted in rapid diagnosis of P. aeruginosa infection. This finding underlined the importance of Pec 1 in the pathogenesis of P. aeruginosa infection and indicated that Pec 1 could be a vital independent virulence factor during chronic infection with P. aeruginosa, providing new insights in rapid diagnosis, therapeutic targets, and vaccine antigens of P. aeruginosa infection.

show abstract

“…Autophagy is a conserved cellular process that is responsible for degradation of intracellular proteins and organelles [ 145 , 146 ]. It can be activated in both normal and stress condition to provide required metabolic substrates for the cell survival.…”

Section: Wnt/β-catenin and Pi3k/akt Signaling Pathwaysmentioning

confidence: 99%

MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma

Palizkaran Yazdi,

Barjasteh,

Moghbeli

2024

Mol Brain

Self Cite

View full text Add to dashboard Cite

Glioblastoma (GBM) is an aggressive nervous system tumor with a poor prognosis. Although, surgery, radiation therapy, and chemotherapy are the current standard protocol for GBM patients, there is still a poor prognosis in these patients. Temozolomide (TMZ) as a first-line therapeutic agent in GBM can easily cross from the blood-brain barrier to inhibit tumor cell proliferation. However, there is a high rate of TMZ resistance in GBM patients. Since, there are limited therapeutic choices for GBM patients who develop TMZ resistance; it is required to clarify the molecular mechanisms of chemo resistance to introduce the novel therapeutic targets. MicroRNAs (miRNAs) regulate chemo resistance through regulation of drug metabolism, absorption, DNA repair, apoptosis, and cell cycle. In the present review we discussed the role of miRNAs in TMZ response of GBM cells. It has been reported that miRNAs mainly induced TMZ sensitivity by regulation of signaling pathways and autophagy in GBM cells. Therefore, miRNAs can be used as the reliable diagnostic/prognostic markers in GBM patients. They can also be used as the therapeutic targets to improve the TMZ response in GBM cells.

show abstract

MicroRNAs as the critical regulators of autophagy-mediated cisplatin response in tumor cells

Cited by 12 publications

References 209 publications

Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α

Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α

Pec 1 of Pseudomonas aeruginosa Inhibits Bacterial Clearance of Host by Blocking Autophagy in Macrophages

MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma

Contact Info

Product

Resources

About